PainReform
PRFX
#10472
Rank
C$5.71 M
Marketcap
C$1.46
Share price
9.75%
Change (1 day)
-65.67%
Change (1 year)

P/E ratio for PainReform (PRFX)

P/E ratio as of December 2025 (TTM): -0.0047

According to PainReform's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0046906. At the end of 2023 the company had a P/E ratio of -0.2614.

P/E ratio history for PainReform from 2023 to 2024

PE ratio at the end of each year

Year P/E ratio Change
2023-0.2614-33.07%
2022-0.3905-14.21%
2021-0.4552-50.63%
2020-0.9220

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Onconova Therapeutics
ONTX
-0.9953 21,119.03%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-5.69 121,153.14%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.